NASDAQ:GTHX G1 Therapeutics - GTHX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.64 -0.15 (-5.38%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.61▼$2.8350-Day Range$2.57▼$8.1652-Week Range$2.55▼$17.49Volume733,672 shsAverage Volume1.33 million shsMarket Capitalization$136.38 millionP/E RatioN/ADividend YieldN/APrice Target$16.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside528.8% Upside$16.60 Price TargetShort InterestBearish7.10% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.81Based on 3 Articles This WeekInsider TradingSelling Shares$204,976 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.98) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector149th out of 1,002 stocksPharmaceutical Preparations Industry60th out of 488 stocks 4.4 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.60, G1 Therapeutics has a forecasted upside of 528.8% from its current price of $2.64.Amount of Analyst CoverageG1 Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.10% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 28.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 3.2 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 21 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat Follows7 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $204,976.00 in company stock.Percentage Held by InsidersOnly 8.09% of the stock of G1 Therapeutics is held by insiders.Percentage Held by Institutions53.13% of the stock of G1 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($1.98) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About G1 Therapeutics (NASDAQ:GTHX) StockG1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.Read More Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comBrokerages Set G1 Therapeutics, Inc. (NASDAQ:GTHX) Price Target at $16.60March 3, 2023 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2022 Earnings Call TranscriptMarch 29, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 2, 2023 | bizjournals.comG1 Therapeutics cuts 30% of workforce, , shakes up C-suiteMarch 2, 2023 | msn.com7 Analysts Have This to Say About G1 TherapeuticsMarch 2, 2023 | finance.yahoo.comQ4 2022 G1 Therapeutics Inc Earnings CallMarch 1, 2023 | bizjournals.comG1 Therapeutics cuts 30% of workforceMarch 1, 2023 | finance.yahoo.comG1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsMarch 29, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 28, 2023 | msn.comG1 Therapeutics's Earnings OutlookFebruary 28, 2023 | finance.yahoo.comG1 Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceFebruary 22, 2023 | finance.yahoo.comG1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023February 17, 2023 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) latest 46% decline adds to one-year losses, institutional investors may consider drastic measuresFebruary 15, 2023 | finance.yahoo.comG1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseFebruary 14, 2023 | reuters.comG1 Therapeutics to halt drug trial in colon cancer, shares plungeFebruary 14, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on G1 Therapeutics (GTHX)February 13, 2023 | msn.comG1 Therapeutics Crashes after Terminating Cancer TrialFebruary 13, 2023 | msn.comHot Stocks: MNDY rose on earnings; FIS drops; FIVE hits 52-week high; GTHX plunges more than 50%February 13, 2023 | finance.yahoo.comG1 Therapeutics stock plummets 50% after trial cut short for cancer drugFebruary 13, 2023 | reuters.comG1 Therapeutics to discontinue cancer drug trial, shares plunge 40%February 13, 2023 | msn.comWhy Is G1 Therapeutics (GTHX) Stock Down 52% Today?February 13, 2023 | finance.yahoo.comG1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)February 13, 2023 | finance.yahoo.comG1 Therapeutics Shelves Pivotal Colorectal Trial, After Trilaciclib Triplet Therapy Favored Placebo ArmFebruary 13, 2023 | finance.yahoo.comG1 to discontinue study of colorectal cancer treatmentFebruary 9, 2023 | finance.yahoo.comFirst Prescription for COSELA® (trilaciclib) Issued in ChinaJanuary 11, 2023 | finance.yahoo.comG1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology ConferenceJanuary 4, 2023 | msn.comG1 Therapeutics posts early mid-stage results for bladder cancer therapySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Company Calendar Last Earnings3/01/2023Today3/28/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.60 High Stock Price Forecast$25.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+528.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,560,000.00 Net Margins-287.63% Pretax Margin-284.32% Return on Equity-209.92% Return on Assets-77.70% Debt Debt-to-Equity Ratio1.12 Current Ratio5.04 Quick Ratio4.59 Sales & Book Value Annual Sales$51.30 million Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.65Miscellaneous Outstanding Shares51,660,000Free Float47,479,000Market Cap$136.38 million OptionableOptionable Beta1.83 Key ExecutivesJack BaileyPresident, Chief Executive Officer & DirectorTerry L. MurdockChief Operating OfficerJennifer K. MosesChief Financial OfficerRajesh K. MalikChief Medical OfficerMark AvaglianoChief Business OfficerKey CompetitorsSpectrum PharmaceuticalsNASDAQ:SPPINektar TherapeuticsNASDAQ:NKTRCitius PharmaceuticalsNASDAQ:CTXRCue BiopharmaNASDAQ:CUEADC TherapeuticsNYSE:ADCTView All CompetitorsInsiders & InstitutionsMorgan StanleyBought 32,379 shares on 2/15/2023Ownership: 0.864%Man Group plcBought 23,760 shares on 2/15/2023Ownership: 0.055%Boothbay Fund Management LLCBought 15,161 shares on 2/15/2023Ownership: 0.035%Legal & General Group PlcBought 11,571 shares on 2/15/2023Ownership: 0.027%Lazard Asset Management LLCBought 10,012 shares on 2/15/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions GTHX Stock - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price forecast for 2023? 6 analysts have issued 1 year price objectives for G1 Therapeutics' stock. Their GTHX share price forecasts range from $10.00 to $25.00. On average, they predict the company's share price to reach $16.60 in the next year. This suggests a possible upside of 517.1% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2023? G1 Therapeutics' stock was trading at $5.43 at the start of the year. Since then, GTHX stock has decreased by 50.5% and is now trading at $2.69. View the best growth stocks for 2023 here. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,670,000 shares, an increase of 28.3% from the February 28th total of 2,860,000 shares. Based on an average trading volume of 1,260,000 shares, the short-interest ratio is presently 2.9 days. View G1 Therapeutics' Short Interest. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its earnings results on Wednesday, March, 1st. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.12. The company had revenue of $10.25 million for the quarter, compared to analyst estimates of $9.61 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 209.92% and a negative net margin of 287.63%. What ETF holds G1 Therapeutics' stock ? Invesco Nasdaq Future Gen 200 ETF holds 4,161 shares of GTHX stock, representing 0.28% of its portfolio. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (6.55%), JPMorgan Chase & Co. (4.74%), Millennium Management LLC (3.90%), Marshall Wace LLP (2.32%), Renaissance Technologies LLC (1.51%) and Raymond James & Associates (1.16%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $2.69. How much money does G1 Therapeutics make? G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $138.97 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. How many employees does G1 Therapeutics have? The company employs 148 workers across the globe. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830. This page (NASDAQ:GTHX) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.